Astellas eyes rare ophthalmology, licensing 4DMT's viral vector for gene therapy for up to $962M
Astellas will pay 4D Molecular Therapeutics $20 million upfront to use its viral vector for a rare monogenic eye disease in a deal worth up to $962 million, the companies announced Monday evening.
Astellas is not disclosing what rare eye disease it plans to target with the adeno-associated virus, or AAV, vector. But it is not one that 4D Molecular Therapeutics, known as 4DMT, is working on already, according to the companies. Astellas also has the option to use the vector for two more rare monogenic diseases down the line.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.